Gliflozins beat other T2DM drugs for lowering kidney stone risk: study
SGLT2 inhibitors trumped GLP-1 receptor agonists and DPP4 inhibitors for reducing nephrolithiasis risk, doctors say.
For adults with type 2 diabetes, initiation of SGLT2 inhibitors may lower the risk for nephrolithiasis, according to a US study in JAMA Internal Medicine.
Doctors from the Brigham and Women’s Hospital in Boston examined the association between type 2 diabetes medication use and the risk for developing nephrolithiasis.
